How is it possible?

That we spend our entire lives searching for the right products to prevent acne and skin cancer

when science can already deliver these

Consolidation Intensification Fails in High-Risk Metastatic Ewing Sarcoma

Curated by Claudia Shannon / Research Scientist / ishonest

Similarly poor outcomes with addition of high-dose treosulfan and melphalan

Adding high-dose treosulfan and melphalan as further consolidation therapy for high-risk metastatic Ewing sarcoma failed to improve survival outcomes, a randomized phase III study showed.

While EFS rates numerically favored the treosulfan-melphalan group at the 1-year mark (51.8% vs 39.8%), rates were similarly low at 3 years (20.09% vs 19.2%), the team reported in the Journal of Clinical Oncology.

ishonest No.501 - Frizzy Hair

Recommended
No.501 - Frizzy Hair

At a median follow-up of 3.3 years, the secondary endpoint of overall survival (OS) was similar between groups, with 30 deaths in the treosulfan-melphalan arm and 31 in the control arm (HR 0.96, 95% CI 0.58-1.58):

  • OS rates at 3 years: 43.4% vs 37.4%, respectively
  • OS rates at 5 years: 26.8% vs 33.6%

"On the basis of these and other findings, we must now acknowledge, once and for all, that further attempts to intensify alkylator-based regimens will not meaningfully break the current EFS ceiling in metastatic EWS [Ewing sarcoma]," wrote Steven DuBois, MD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center in Boston, and colleagues, in an editorial accompanying the study. "The current trial simply adds to the totality of evidence over the decades that further chemotherapy intensification is not going to improve outcomes."

DuBois's group suggested that treatment strategies in need of further study for high-risk Ewing sarcoma include targeted therapy approaches, innovative local treatments for primary and metastatic lesions, and novel maintenance regimens.

There have been advances in immunotherapy approaches for other sarcomas, they noted, as well as activity when oncogenic fusion drivers are targeted with selective inhibitors, such as in NTRK translocation-driven sarcomas.

The Natural Way To Improve Skin Elasticity

Learn more

"To translate these successes to high-risk EWS, we will need a renewed investment in laboratory research and early phase clinical trials, with promising findings from the early phase clinic rapidly advanced to frontline trials," they concluded. "Only then will we break the ceiling and see a major increase in cure rates for high-risk EWS."

The current trial, EWING 2008R3, was conducted in a dozen countries from 2009 to 2018 and included 109 patients (median age 15.8 years, 56% male) who, along with standard induction and consolidation regimens, were randomly assigned 1: 1 to high-dose treosulfan-melphalan consolidation or no additional therapy.

Eligible patients had disseminated Ewing sarcoma with metastases to the bone and/or other sites -- the study excluded those with only pulmonary metastases. All patients received six cycles of vincristine, ifosfamide, doxorubicin, and etoposide induction, and then eight cycles of vincristine, actinomycin D, and cyclophosphamide consolidation.

The primary endpoint was EFS, defined as the time from randomization to first progression, relapse, secondary malignancy, or death. A total of 82 events were reported (39 in the study arm and 43 among controls). The EFS results were similar in the study's per-protocol set of 87 patients.

Read more on: othercancers, fails


What we do

We make skincare treatments and customize them for your skin-related problems, genetics, lifestyle, and environment.

How you benefit

You get total control over your skincare and the choice to change your skin. An impossible has just become possible.

How it Works

Outline of microscope

Create Treatment

Our algorithm creates a unique routine with a few customized products. The algorithm uses 50+ years of skincare research.

Outlines of Packaging

Divide and Rule

Every product is designed for one problem. Apply the product when the problem appears. Much like you treat flu or headache.